It's a STAMPEDE of ASCO news.

June 6, 2017. It's that time of year, so open wide for the fire hose. STAMPEDE and LATITUDE are phase III trials reporting early data at ASCO 2017. Both are looking at adding abiraterone to ADT upfront for metastatic (STAMPEDE and LATITUDE) and locally advanced (STAMPEDE) prostate CA. Both show significantly improved overall survival and disease control. But remember, abiraterone can cause liver toxicity and blood pressure issues. Next step is to combine abiraterone with docetaxel, which also improves survival in this setting. Stay tuned.


Popular Posts